Cazenove Private Equity

Cazenove Private Equity was the venture capital and private equity division of the historic British investment bank Cazenove. The firm was a prominent investor in the life sciences and healthcare sectors, managing dedicated funds such as the Cazenove Life Sciences Fund which targeted innovative biotechnology and medical device companies. Its portfolio included notable successes such as Oxford Immunotec and Confluent Surgical, reflecting a strong focus on growth-stage companies in Europe and North America. In 2013, Cazenove Capital Management was acquired by Schroders, leading to the integration of its private equity operations into Schroders' alternative investment platform. The firm played a significant role in financing the European biotech ecosystem during the late 1990s and 2000s.